| Literature DB >> 31842764 |
A Damlin1,2,3, K Westling4,5, E Maret6,7, C Stålsby Lundborg8, K Caidahl6,7,9,10, M J Eriksson6,7.
Abstract
BACKGROUND: The diagnosis of infective endocarditis (IE) is based on microbiological analyses and diagnostic imaging of cardiac manifestations. Echocardiography (ECHO) is preferred for visualization of IE-induced cardiac manifestations. We investigated associations between bacterial infections and IE manifestations diagnosed by ECHO.Entities:
Keywords: Cardiac imaging; Diagnostics; Echocardiography; Heart valves; Infective endocarditis
Mesh:
Year: 2019 PMID: 31842764 PMCID: PMC6916238 DOI: 10.1186/s12879-019-4682-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Descriptive data of IE-patients admitted to the Karolinska University Hospital (KUH) from 2008 to 2017
| 492 (100) | |
| Women | 161 (33) |
| Men | 331 (67) |
| Age, mean (± SD); medians (25th and 75th percentiles) | 57.1 (18.4); 57 (44.5, 72) |
| History of IV drug abuse | 156 (32) |
| Bicuspid aortic valve | 18 (4) |
| vProsthetic valve | 92 (19) |
| CIED | 50 (10) |
| Rheumatic heart disease | 2 (0) |
| Congenital heart disease | 7 (1) |
| History of IE | 78 (16) |
| Known valvular disease | 75 (15) |
| Heart failure before or under IE treatment | 60 (12) |
| Fever | 432 (88) |
| Vascular phenomena | 210 (43) |
| New heart murmur | 77 (16) |
Notes: vales are presented in n = number of patients and % of all patients in parenthesis. Abbreviations: CIED, cardiovascular implantable electronic device; IE, infective endocarditis; IV, intravenous; KUH, Karolinska University Hospital; SD, standard deviation
Distribution of IE-manifestations and bacterial species comprising 90% of the etiologies among patients with IE
| Aortic valve vegetation | Mitral valve vegetation | Tricuspid valve vegetation | Pulmonary valve vegetation | CIED-associated IE | Perivalvular abscess | Total, n (%) | |
|---|---|---|---|---|---|---|---|
| All patients, n (%) | 190 (39) | 195 (40) | 108 (22) | 9 (2) | 24 (5) | 29 (6) | |
| 84 (17), 0.69, 0.47–1.01; 0.05 | 11 (2), 0.89, 0.35–2.20; 0.78 | 11 (2), 0.63, 0.26–1.44; 0.24 | 239 (49) | ||||
| CoNS | 6 (1), 0.49, 0.16–1.33; 0.13 | 2 (0), 0.31, 0.03–1.30; 0.13 | 0 (0) | 24 (5) | |||
| Viridans group streptococci | 45 (9), 1.33, 0.84–2.12; 0.20 | 0 (0) | 6 (1), 1.00, 0.32–2.61; 1.00 | 102 (21) | |||
| Group B streptococci | 4 (1), 0.91, 0.19–3.62; 1.00 | 0 (0) | 0 (0) | 0 (0) | 1 (0), 1.62, 0.04–12.11; 0.49 | 11 (2) | |
| Group D streptococci | 3 (1), 1.20, 0.17–7.15; 1.00 | 4 (1), 2.05, 0.34–14.14; 0.44 | 0 (0) | 0 (0) | 0 (0) | 1 (0), 2.70, 0.06–23.37; 0.35 | 7 (1) |
| Group G streptococci | 4 (1), 1.60, 0.29–8.70; 0.49 | 3 (1), 0.91, 0.14–4.73; 1.00 | 1 (0), 0.50, 0.01–3.99; 1.00 | 0 (0) | 0 (0) | 0 (0) | 8 (2) |
| 19 (4), 0.93, 0.48–1.75; 0.80 | 7 (1), 0.55, 0.20–1.28; 0.15 | 0 (0) | 2 (0), 0.80, 0.09–3.41; 1.00 | 2 (0), 0.64, 0.07–2.69; 0.76 | 50 (10) | ||
| HACEK | 6 (1), 1.06, 0.31–3.40; 0.91 | 3 (1), 0.37, 0.07–1.40; 0.18 | 2 (0), 0.54, 0.06–2.44; 0.54 | 1 (0) 4.19, 0.09–34.97; 0.25 | 1 (0), 1.15, 0.03–8.07; 0.60 | 15 (3) |
Notes: The table represents all included patients, with native and prosthetic valves analyzed together. Values are presented in n = number of patients, (% of patients), odds ratio, 95% confidence interval; P-value. Statistically significant associations (P < 0.05) are shown in bold. Abbreviations: CIED, cardiovascular implantable electronic device; CoNS, coagulase-negative staphylococci; E, enterococcus; HACEK, Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae; IE, infective endocarditis; KUH, Karolinska University Hospital, S, staphylococcus
Distribution of bacterial etiologies, predisposing factors and outcomes among patients with IE at the KUH
| Prosthetic heart valve | IV drug abuse | > 1 ECHO manifestation | Surgical treatment for IE | In-hospital mortality | |
|---|---|---|---|---|---|
| All patients, n (%) | 92 (19) | 156 (32) | 83 (17) | 139 (28) | 33 (7) |
| 36 (43), 0.78, 0.47–1.28; 0.30 | 61 (44), 0.77, 0.51–1.16; 0.19 | 21 (64), 1.93, 0.88–4.42; 0.07 | |||
| CoNS | 8 (9), 2.29, 0.82–5.88; 0.06 | 10 (7), 1.88, 0.73–4.67; 0.13 | 2 (6), 1.28, 0.14–5.62; 0.67 | ||
| Viridans group streptococci | 14 (15), 0.64, 0.32–1.20; 0.15 | 14 (17), 0.74, 0.37–1.41; 0.34 | 34 (24), 1.36, 0.82–2.22; 0.20 | 6 (18), 0.84, 0.28–2.16; 0.71 | |
| Group B streptococci | 1 (1), 0.43, 0.01–3.09; 0.70 | 0 (0) | 2 (2), 1.10, 0.11–5.44; 1.00 | 3 (2), 0.95, 0.16–4.04; 1.00 | 1 (3), 1.38, 0.04–10.22;0.54 |
| Group D streptococci | 3 (3), 3.34, 0.48–20.04; 0.13 | 0 (0) | 1 (1), 0.82, 0.02–6.89; 1.00 | 4 (3), 3.46, 0.57–23.84; 0.10 | 0 (0) |
| Group G streptococci | 2 (2), 1.46, 0.14–8.33; 0.65 | 1 (1), 0.30, 0.01–2.40; 0.45 | 0 (0) | 1 (1), 0.36, 0.01–2.83; 0.45 | 0 (0) |
| 17 (11), 1.12, 0.57–2.16; 0.71 | 11 (13), 1.45, 0.64–3.05; 0.31 | 9 (6), 0.53, 0.22–1.14; 0.09 | 2 (6), 0.55, 0.06–2.29; 0.56 | ||
| HACEK | 5 (5), 2.24, 0.58–7.39; 0.17 | 0 (0) | 4 (5), 1.83, 0.41–6.38; 0.30 | 1 (3), 0.99, 0.03–6.94; 1.00 |
Notes: Values are presented in n = number of patients, (% of patients), odds ratio, 95% confidence interval; P-value. Statistically significant associations (P < 0.05) are shown in bold. Abbreviations: CoNS, coagulase-negative staphylococci; ECHO, echocardiography; HACEK, Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae; IE, infective endocarditis; IV, intravenous; KUH, Karolinska University Hospital
Distribution of ECHO-manifestations, predisposing factors and outcomes among patients with IE at the KUH
| IV drug abuse | Surgical treatment for IE | In-hospital mortality | |
|---|---|---|---|
| All patients, n (%) | 156 (32) | 139 (28) | 33 (7) |
| Aortic valve vegetation | 17 (52), 1.76, 0.81–3.82; 0.12 | ||
| Mitral valve vegetation | 64 (46), 1.45, 0.95–2.19; 0.07 | 15 (45), 1.29, 0.59–2.79; 0.48 | |
| Tricuspid valve vegetation | 3 (9), 0.34, 0.06–1.12; 0.08 | ||
| Pulmonary valve vegetation | 1 (1), 0.31, 0.01–2.37; 0.46 | 0 (0) | |
| CIED IE | 2 (6), 1.28, 0.14–5.61; 0.67 | ||
| Perivalvular abscess | |||
| Prosthetic heart valve | 26 (19), 1.00, 0.58–1.69; 1.00 | 8 (24), 1.43, 0.54–3.41; 0.40 |
Notes: Values are presented in n = number of patients, (% of patients), odds ratio, 95% confidence interval; P-value. Statistically significant associations (P < 0.05) are shown in bold. Abbreviations: CIED, cardiovascular implantable electronic device; IE, infective endocarditis; IV, intravenous; KUH, Karolinska University Hospital
Trends of ECHO-manifestations, predisposing factors and outcomes among patients with IE from 2008 to 2017
| t | p-value | |
|---|---|---|
| Aortic valve vegetation | −1.27 | 0.21 |
| Mitral valve vegetation | 4.18 | |
| Tricuspid valve vegetation | −3.01 | |
| Pulmonary valve vegetation | 0.05 | 0.96 |
| CIED-associated IE | −0.29 | 0.77 |
| Perivalvular abscess | −0.39 | 0.70 |
| In-hospital mortality | 0.16 | 0.87 |
| IV drug abuse | −3.33 | |
| Prosthetic valve IE | 0.82 | 0.41 |
| Surgical treatment for IE | 2.11 |
Notes: Value for trend (t), is obtained by linear regression. Statistically significant values (P < 0.05) are shown in bold. Abbreviations: CIED, cardiovascular implantable electronic device; ECHO, echocardiography; IE, infective endocarditis; IV, intravenous
Fig. 1(attached separately). Trends of ECHO-manifestations, IV drug abuse and surgical treatment among patients with IE from 2008 to 2017. Notes: The y-axis presents the percentage of patients of all patients with IE during each year. Values for trend (t), followed by p-values are: mitral valve vegetation (t = 4.18; P < 0.01), tricuspid valve vegetation (t = − 3.01; P < 0.01), IV drug abuse (t = − 3.33; P < 0.01), surgical treatment for IE (T = 2.11; P = 0.04). Abbreviations: ECHO, echocardiography; IE, infective endocarditis; IV, intravenous